1994 Volume 42 Issue Supplement4 Pages 477-485
We studied the antimicrobial activity of a new carbapenem antibiotic, biapenem (BIPM), and its clinical value in urinary tract infection (UTI).
1. BIPM possessed excellent antimicrobial activity against both of gram-positive cocci and gramnegative rods in 20 reference strains tested in this study. MICs of BIPM were 3.13μg/ml or lower. Against MRSA isolated from UTI, the antimicrobial activity of BIPM was as low as those of imipenem and meropenem. Against Enterococcus faecalis, the antimicrobial activity of BIPM was also low, though it was higher than cefepime. Against clinical isolates of gram-negative rods including Pseudomonas aeruginosa, the antimicrobial activity of BIPM was higher than that of imipenem and corresponded to that of meropenem.
2. Fifteen patients with complicated UTI were treated with 0.15g, 0.3g or 0.45g of BIPM twice a day for 5 days. The therapeutic efficacy was evaluated according to the criteria proposed by the Japanese UTI Committee. The clinical efficacy was excellent or moderate in 6 of 7 cases, in 5 of 6, in 2 of 2 with a dose of 0.15g, 0.3g, 0.45g, respectively.
Of all the 15 patients treated with BIPM in this study, the clinical efficacy was excellent in 5 patients, moderate in 8 patients and poor in 2 patients so that the overall efficacy rate was 87%.
3. Of 15 patients treated with BIPM, one patient showed eosinophilia and another patient showed elevation of GPT. In the remaining 13 patients, there were no significant clinical or laboratory adverse reactions.
Therefore, this study demonstrated BIPM to be an effective and safe drug in the treatment of complicated UTI.
